Skip to content

    Cosmo First

    COSMOFIRST
    Capital Goods·21 May 2025
    Management Summary

    Cosmo First reported strong Q4 and FY25 results, with significant growth in sales, EBITDA, and PAT, driven by specialty film sales and cost rationalization. The company is nearing completion of a substantial capex cycle, with new CPP and Sunshield lines operational, and a new BOPP line expected in Q1 FY26. While profitability in new ventures like Zigly is still evolving, management is optimistic about future growth and asset utilization, targeting ₹3500-4000 crores in revenue for FY26.

    Highlights

    5
    • Consolidated sales for Q4 FY25 increased 16% YoY to ₹746 crores, backed by higher specialty sales and improved BOPP margins.

    • Full Year FY25 EBITDA surged 44% to ₹362 crores, primarily due to 10% growth in specialty sales and ₹25 crores in cost rationalization.

    • Consolidated PAT for FY25 more than doubled, increasing 115% to ₹133 crores.

    • New CPP line (22,000 MT capacity) started operations in March 2025, and Sunshield film began commercial production in May 2025.

    • The new BOPP line, with 81,000 MT capacity, is expected to be operational by Q1 FY26 and is noted as one of the lowest cost production lines.

    Concerns

    4
    • Q4 FY25 EBITDA was impacted by ₹4.3 crores in one-time costs for shifting a thermal line and a 10% lower volume on the BOPET film line due to planned maintenance.

    • ROCE/ROE for FY25 is currently below the cost of capital, as significant debt for new capex is on the books but returns are yet to fully materialize.

    • Zigly's product side margins remain low, and vet care services are not yet profitable, though some older stores are breaking even.

    • Potential temporary blip in BOPP margins due to 4-5 new lines expected to come up in India in the current financial year.

    What Changed1

    vs Q1 FY26

    Guidance items14 → 10 (-4)
    Key financials

    Metrics

    6

    Periods

    2

    Q4 FY25

    3
    • Consolidated Sales
      ₹746 Cr
      YoY+16%
    • Consolidated EBITDA
      ₹85 Cr
      YoY+26.9%
    • BOPP Film Margin
      21 Rs/kg
      YoY+50%

    FY25

    3
    • Consolidated EBITDA
      ₹362 Cr
      YoY+44%
    • Consolidated PAT
      ₹133 Cr
      YoY+115.0%
    • Specialty Sales Growth
      10%

    Segment breakdown

    Specialty Chemical Subsidiary
    ₹180 Cr Top Line (FY25) EBITDA Margin
    Cosmo Consumer (Sun Control Films)
    ₹25 Cr Revenue Target (FY26)₹50 Cr Revenue Target (FY27)₹35 Cr Break-even Sales
    Zigly (Pet Care)
    ₹5 Cr Monthly GMV60% Sales Split (Products)40% Sales Split (Services)32 stores Store Count5% Retail Level Growth
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹200 crores

    largely done through internal accrual

    Debt

    Net ₹967 crores · 2.7x EBITDA

    Dividend

    ₹4/share (final)

    Guidance & targets

    10
    CategoryTargetPriority
    Revenue
    Specialty Sales Growth
    better off than 10%
    Medium
    Revenue
    Cosmo Consumer (Sun Control Films) Revenue
    ₹25-30 crores
    High
    Revenue
    Cosmo Consumer (Sun Control Films) Revenue
    exceed ₹50 crores
    High
    Revenue
    Total Revenue with Full Utilization
    ₹5000 crores
    Medium
    Revenue
    Total Sales
    ₹3500-4000 crores
    High
    Profitability
    Cosmo Consumer (Sun Control Films) Break-even Sales
    ₹35 crores
    High
    Profitability
    BOPET Film Margins
    improve
    Medium
    Profitability
    New BOPP Line Monthly Gross Margin
    ₹7.5 crores
    High
    Capacity
    New BOPP Line Operation
    Q1 FY26
    High
    Capital Allocation
    Pet Care Business Demerger
    within 3-4 years
    Medium

    New BOPP Line Commissioning

    next quarter
    CurrentExpected Q1 FY26
    TargetCommercial operations started

    Why it matters

    This new line is a major capex investment and is expected to significantly contribute to revenue and profitability.

    The BOPP line having an annual capacity of close to 81,000 metric ton, is also expected to start operation from Q1 of FY'26.

    How to verify

    capital_allocation.capex.purposes

    Risks & concerns

    3
    RiskSeverity

    BOPP oversupply and margin pressure

    4-5 new BOPP lines coming up in India may cause a temporary blip in BOPP margins, though the company's focus on specialty films and lowest cost production should mitigate.Management acknowledged

    medium

    ROCE/ROE below cost of capital

    Current ROCE is subdued because significant debt for new capex is already on the balance sheet, but the returns from these investments are yet to fully kick in.Management acknowledged

    medium

    Zigly profitability challenges

    Product side margins are low due to supplier terms, and vet care services are not yet profitable, requiring a focus on private labels and services to improve.Management acknowledged

    medium

    Q&A highlights

    7

    “Well frankly, in our past experience the Specialty Film margins broadly remain the same, except there may be some minor changes due to change in the mix. Semi specialty runs with a additional delta over the commodity. But the relationship is not linear, so let us say if commodity margins moves by Rs.10 or so, it's not necessary semi specialty margin will also change by 10. It may change by Rs.4, Rs.5 or Rs.6, depending on the criticality of the film. To answer your question, in the specialty film, largely the margins are protected. Semi specialty changes with the change in the commodity but delta is lower compared to the change in the commodity.”

    Clarifies that specialty film margins are largely protected from commodity price volatility, which is key for the company's strategy.

    asked by Neerav from Anvil Wealth

    3 min read6 chapters

    Detailed Narrative

    01

    Q4 & FY25 Performance Overview

    Cosmo First reported consolidated sales of ₹746 crores for Q4 FY25, marking a 16% increase from the March 2024 quarter, driven by higher specialty sales and improved BOPP margins. The company's EBITDA for the quarter stood at ₹85 crores, up from ₹67 crores in the prior year, despite a ₹4.3 crore one-time📎 cost and a 10% volume reduction in BOPET due to planned maintenance. For the full fiscal year FY25, consolidated EBITDA grew 44% to ₹362 crores, with PAT increasing by 115% to ₹133 crores, primarily attributed to a 10% growth in specialty sales and ₹25 crores in cost rationalization.

    02

    Strategic Investments & Capacity Expansion

    The company has invested approximately ₹1180 crores in capex over the last three years across various growth projects, including BOPP, CPP, polyester, metallizer, coating lines, Sunshield, Paint Protection Film, and rigid packaging. The new 22,000 metric ton CPP line commenced operations in March 2025, and the Sunshield film began commercial production in May 2025. A new BOPP line with an 81,000 metric ton capacity is expected to be operational by Q1 FY26, which management states is one of the lowest cost production lines available. An additional ₹200+ crores in capex is planned for FY26, largely funded by internal accruals, focusing on specialty and value-added lines.

    03

    Specialty Films & Margin Dynamics

    Cosmo First's strategy emphasizes specialty film sales, which have grown at a 10% CAGR over the past six years, with a similar growth rate in FY25. The company's specialty film portfolio currently represents 71% of its total film sales, split broadly 50:50 between semi-specialty and specialty. Management noted that specialty film margins are largely protected from commodity price fluctuations, with semi-specialty margins showing a lower delta to commodity changes. While BOPET margins are expected to improve due to limited new capacity, BOPP margins might experience a temporary blip📎 in the short term due to several new lines coming up in India.

    04

    New Business Verticals: Cosmo Consumer & Zigly

    The company is expanding its new business verticals. The Specialty Chemical subsidiary achieved a top line of ₹180 crores in FY25 with high-teens EBITDA. The new Cosmo Consumer vertical, encompassing Sunshield and Paint Protection Film, is projected to generate ₹25-30 crores in FY26 and exceed ₹50 crores by FY27, with a break-even sales target of ₹35 crores. The pet care vertical, Zigly, currently operates 32 stores and has a monthly GMV of ₹5 crores, with sales split 60% products and 40% services. Zigly is focusing on private labels and services to improve profitability, as product margins remain a challenge.

    05

    Capital Structure & Shareholder Returns

    As of March 31, 2025, Cosmo First's net debt stood at ₹967 crores, resulting in a net debt to EBITDA ratio of 2.7x and a debt to equity ratio of 0.7 times. The Board of Directors has recommended a dividend of ₹4 per equity share for FY24-25, subject to shareholder approval. Management acknowledged that the current ROCE is subdued and below the cost of capital, primarily because the debt associated with recent large-scale capex is already on the books, while the full returns from these maturing assets are yet to be realized.

    06

    Outlook & Growth Drivers

    Cosmo First anticipates FY26 sales to be in the range of ₹3500-4000 crores, with potential to reach ₹5000 crores with full utilization of all assets. The company expects specialty sales growth to be even better in FY26 than the 10% achieved in FY25. The new BOPP line is projected to generate a monthly gross margin of ₹7.5 crores at 90% utilization. The company plans to demerge its pet care business within the next three to four years, once it achieves decent scale and significantly reduces losses. The focus remains on leveraging new investments, expanding international geographies, and further cost rationalization.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.